These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18257545)

  • 1. Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
    Colabufo NA; Berardi F; Perrone R; Rapposelli S; Digiacomo M; Vanni M; Balsamo A
    J Med Chem; 2008 Mar; 51(5):1415-22. PubMed ID: 18257545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
    Chan KF; Wong IL; Kan JW; Yan CS; Chow LM; Chan TH
    J Med Chem; 2012 Mar; 55(5):1999-2014. PubMed ID: 22320402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors.
    Colabufo NA; Berardi F; Perrone MG; Cantore M; Contino M; Inglese C; Niso M; Perrone R
    ChemMedChem; 2009 Feb; 4(2):188-95. PubMed ID: 19140144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Ren Z; Peng H; Peng S; Zhang Y
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):318-22. PubMed ID: 25446092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
    Liu XL; Tee HW; Go ML
    Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.
    Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A
    Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships.
    Häcker HG; Leyers S; Wiendlocha J; Gütschow M; Wiese M
    J Med Chem; 2009 Aug; 52(15):4586-95. PubMed ID: 19580319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.